Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 04 - 19 tags : Drug save search
What's New Related to Drugs
Published: 2021-04-19 (Crawled : 00:00) - fda.gov
BDX | $232.77 -0.68% 250K
|
Health Technology
|
| O: -0.09%
H: 0.73%
C: -0.88%
drug
Pyxis Oncology Hosting Key Opinion Webinar on Antibody-Drug ConjugatesWebinar on Tuesday, April 27th @ 1pmET
Published: 2021-04-19 (Crawled : 14:00) - biospace.com/
JNJ | News | $147.27 -1.53% 2.3M
|
Health Technology
|
| O: 0.16%
H: 0.38%
C: 0.12%
antibody drug
J&J, Teva and Other Opioid Drugmakers Face $50 Billion Lawsuit in California
Published: 2021-04-19 (Crawled : 13:00) - biospace.com/
JNJ | News | $147.27 -1.53% 2.3M
|
Health Technology
|
| O: 0.16%
H: 0.38%
C: 0.12%
opioid drug
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
Published: 2021-04-19 (Crawled : 13:00) - biospace.com/
CRIS | $15.07 0.4% 710
|
Health Technology
|
| O: -2.52%
H: 1.7%
C: -7.95%
treatment fda drug ca-4948 designation aml
Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR™ Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Published: 2021-04-19 (Crawled : 13:00) - globenewswire.com
ALLO | $3.175 -5.79% 270K
|
Health Technology
|
| O: -1.54%
H: 1.91%
C: 1.03%
food treatment drug clearance
Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI™ With New Drug Application Submitted to the FDA
Published: 2021-04-19 (Crawled : 11:00) - biospace.com/
UTHR | $239.29 2.06% 86K
|
Health Technology
|
| O: 0.6%
H: 0.11%
C: -0.54%
MNKD | $4.285 3.01% 640K
|
Health Technology
|
| O: -0.24%
H: 1.68%
C: -0.24%
new drug fda drug milestone
United Therapeutics Announces Submission of Tyvaso DPI™ New Drug Application to FDA
Published: 2021-04-19 (Crawled : 10:00) - prnewswire.com
UTHR | $239.29 2.06% 86K
|
Health Technology
|
| O: 0.6%
H: 0.11%
C: -0.54%
MNKD | $4.285 3.01% 640K
|
Health Technology
|
| O: -0.24%
H: 1.68%
C: -0.24%
new drug fda drug submission application
FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic CancerXBiotech’s New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer
Published: 2021-04-19 (Crawled : 10:00) - biospace.com/
XBIT | $8.24 0.73% 3K
|
Health Technology
|
| O: 4.1%
H: 0.0%
C: -4.23%
new drug fda therapy cancer biotech drug iot pancreatic pancreas
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CSSE 4 | $0.3686 142.02% 76M
|
Consumer Services
CZOO | $11.685 134.17% 7.6M
|
BOF | $1.93 64.96% 55M
|
AMST | $3.14 57.0% 59M
|
Technology Services
LICN | $0.7885 40.8% 11M
|
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.7 35.53% 6.4M
|
Information
WHLM | $6.61 30.12% 400K
|
Commercial Services
RILY | $27.91 28.5% 8.9M
|
Finance
RBBN 4 | $3.25 26.46% 1.5M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.